PICO Portalanswers from OpenAlex & ORCID
Kim Papp
ResearcherPublications, citations & collaboration network
Kim Papp is a researcher indexed in PICO Portal from OpenAlex & ORCID.
How many works does Kim Papp have?
PICO Portalindexed works
Kim Papp has 816 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Kim Papp have?
PICO Portalcitation count
Kim Papp has 49,985 citations in the OpenAlex counts PICO Portal stores.
What is the h-index of Kim Papp?
PICO Portalh-index
Kim Papp has an h-index of 108 in OpenAlex.
What is the i10-index of Kim Papp?
PICO Portali10-index
Kim Papp has an i10-index of 370 in OpenAlex.
What is the ORCID of Kim Papp?
PICO Portalorcid
The ORCID for Kim Papp is on the source record.
What is the OpenAlex record for Kim Papp?
PICO Portalopenalex
The OpenAlex for Kim Papp is on the source record.
What are the most-cited papers on Kim Papp?
PICO Portalmost cited works
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi, Alexa B. Kimball, Kim Papp, Newman Yeilding, Cynthia Guzzo, Yuhua Wang, Shu Li, Lisa T. Dooley, Kenneth B. Gordon
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim Papp, Richard G. Langley, Mark Lebwohl, Gerald G. Krueger, Philippe Szapary, Newman Yeilding, Cynthia Guzzo, Ming-Chun Hsu, Yuhua Wang, Shu Li, Lisa T. Dooley, Kristian Reich
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham, Jennifer Clay Cather, Jamie Weisman, David M. Pariser, Eric L. Simpson, Kim Papp, Hyuck-Ki Hong, Diana Rubel, Peter Foley, Errol P. Prens, C.E.M. Griffiths, Takafumi Etoh, Pedro Herranz, Ramón M. Pujol, Jacek C. Szepietowski, Karel Ettler, Lajos Kemény, Xiaoping Zhu, Bolanle Akinlade, Thomas Hultsch, Vera Mastey, Abhijit Gadkari, Laurent Eckert, Nikhil Amin, Neil M.H. Graham, Gianluca Pirozzi, Neil Stahl, George D. Yancopoulos, Brad Shumel
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Alan Menter, Stephen K. Tyring, Kenneth B. Gordon, Alexa B. Kimball, Craig L. Leonardi, Richard G. Langley, Bruce Strober, Martin Kaul, Yihua Gu, Martin M. Okun, Kim Papp
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
Andrew Blauvelt, Kim Papp, C.E.M. Griffiths, B. Randazzo, Yasmine Wasfi, Yaung‐Kaung Shen, Shu Li, Alexa B. Kimball